Well.... we have finally witnessed confirmation that the phase 3 trial of CHF will go ahead as we've been told for so long and so often.
I can only assume share price weakness over the last year was due to Teva acquiring Cephalon and the risk it posed for the deal Mesoblast had with Cephalon around the CHF phase 3 trial. I do believe, as it has been mentioned recently on this HC forum, that Teva are gearing up for their investment in regenerative medicine with MSB being their big ticket item. Teva are culling dead wood to help push into this new paradigm.
Now that phase 3 is formalised, anyone want to speculate whether MSB will reach new SP highs?
This is my opinion only. DYOR
Go the blaster!
Ann: FDA Clears Phase 3 Heart Failure Trial , page-7
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |